The cost-effectiveness of 23-valent pneumococcal vaccine in Catalonia, Spain

被引：0
|
作者：
Plans-Rubió, P [1 ]
机构：
[1] Dept Sanitat Catalonia, Barcelona, Spain
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61921-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：754 / 754
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL VACCINES 13 AND 23-VALENT IN HIGH RISK ADULTS IN COLOMBIA
    Ordonez Molina, J. E.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    VALUE IN HEALTH, 2013, 16 (07) : A667 - A667
  • [22] Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain)
    Navas, E
    Salleras, L
    Gisbert, R
    Domínguez, A
    Timoner, E
    Ibáñez, D
    Prat, A
    VACCINE, 2005, 23 (17-18) : 2342 - 2348
  • [23] Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China
    Sun, Xiaodong
    Tang, Yuekun
    Ma, Xiaoying
    Guo, Xiang
    Huang, Zhuoying
    Ren, Jia
    Qiu, Jing
    Jiang, Hongli
    Lu, Yihan
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [24] Cost-effectiveness of the use 23-valent pneumococcal polysaccharide vaccine to prevent secondary bacterial infections related to pandemic influenza in Brazil
    O'Brien, M.
    Dhankhar, P.
    Grabenstein, J.
    Dasbach, E. J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E449 - E450
  • [25] 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia
    Tanimoto, Tetsuya
    Kusumi, Eiji
    Hosoda, Kazutaka
    Hamaki, Tamae
    Takahashi, Kenzo
    LANCET INFECTIOUS DISEASES, 2017, 17 (07): : 692 - 693
  • [26] 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia
    Suzuki, Motoi
    Dhoubhadel, Bhim Gopal
    Katoh, Shungo
    Ariyoshi, Koya
    Morimoto, Konosuke
    LANCET INFECTIOUS DISEASES, 2017, 17 (08): : 803 - 804
  • [27] COST-EFFECTIVENESS ANALYSIS OF SEQUENTIAL VACCINATION OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPSV23) ON ADULT POPULATION IN SOUTH KOREA
    Park, D.
    Kang, S.
    VALUE IN HEALTH, 2017, 20 (09) : A788 - A788
  • [28] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in Navajo adults
    Benin, A
    O'Brien, K
    Watt, J
    Reid, R
    Zell, ER
    Katz, S
    Donaldson, C
    Parkinson, A
    Schuchat, A
    Santosham, M
    Whitney, CG
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1148 - 1148
  • [29] The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales
    Melegaro, A
    Edmunds, WJ
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2004, 19 (04) : 365 - 375
  • [30] The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales
    Melegaro A.
    Edmunds W.J.
    European Journal of Epidemiology, 2004, 19 (4) : 365 - 375
12345